Chi-Med Initiates HMPL-523 Clinical Trials in Hematological Cancer in China
Hutchison China MediTech Limited announces that it has initiated a Phase I trial of its novel spleen tyrosine kinase (“Syk”) inhibitor, HMPL-523, in patients with hematological…
Read More...
Read More...
